Nurix Therapeutics' Roche Deal Seen Driving Long-Term Upside, RBC Capital Markets Says

MT Newswires Live07-10

Nurix Therapeutics (NRIX) is well positioned for long-term growth, with its Roche partnership expanding the commercial opportunity for lead investigational cancer drug bexobrutideg and immunology and inflammation opportunities continuing to offer potential, RBC Capital Markets said in a note Thursday.

Roche's expertise should enhance the market potential for bexobrutideg in chronic lymphocytic leukemia while reducing development costs, the investment firm said, as it raised its estimates for bexobrutideg's US opportunity to $1.7 billion from $1.4 billion previously.

The firm also sees the company's inflammation and immunology pipeline as an underappreciated growth driver, with multiple clinical catalysts expected later this year.

RBC Capital Markets raised its price target to $33 from $30, while maintaining an outperform, speculative risk rating on Nurix.

Shares of Nurix were down 1.1% in premarket activity Friday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2650106180?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-10 20:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2650106180","market":"fut","top_or_hot":-1,"title":"Nurix Therapeutics' Roche Deal Seen Driving Long-Term Upside, RBC Capital Markets Says","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/NRIX\">Nurix Therapeutics</a> (NRIX) is well positioned for long-term growth, with its Roche partnership expanding the commercial opportunity for lead investigational cancer drug bexobrutideg and immunology and inflammation opportunities continuing to offer potential, RBC Capital Markets said in a note Thursday.</p><p>Roche's expertise should enhance the market potential for bexobrutideg in chronic lymphocytic leukemia while reducing development costs, the investment firm said, as it raised its estimates for bexobrutideg's US opportunity to $1.7 billion from $1.4 billion previously.</p><p>The firm also sees the company's inflammation and immunology pipeline as an underappreciated growth driver, with multiple clinical catalysts expected later this year.</p><p>RBC Capital Markets raised its price target to $33 from $30, while maintaining an outperform, speculative risk rating on Nurix.</p><p>Shares of Nurix were down 1.1% in premarket activity Friday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nurix Therapeutics' Roche Deal Seen Driving Long-Term Upside, RBC Capital Markets Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNurix Therapeutics' Roche Deal Seen Driving Long-Term Upside, RBC Capital Markets Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-10 20:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/NRIX\">Nurix Therapeutics</a> (NRIX) is well positioned for long-term growth, with its Roche partnership expanding the commercial opportunity for lead investigational cancer drug bexobrutideg and immunology and inflammation opportunities continuing to offer potential, RBC Capital Markets said in a note Thursday.</p><p>Roche's expertise should enhance the market potential for bexobrutideg in chronic lymphocytic leukemia while reducing development costs, the investment firm said, as it raised its estimates for bexobrutideg's US opportunity to $1.7 billion from $1.4 billion previously.</p><p>The firm also sees the company's inflammation and immunology pipeline as an underappreciated growth driver, with multiple clinical catalysts expected later this year.</p><p>RBC Capital Markets raised its price target to $33 from $30, while maintaining an outperform, speculative risk rating on Nurix.</p><p>Shares of Nurix were down 1.1% in premarket activity Friday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NRIX","symbol_name":"Nurix Therapeutics","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2650106180","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2650106180","pubTimestamp":1783687117,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Nurix Therapeutics  is well positioned for long-term growth, with its Roche partnership expanding the commercial opportunity for lead investigational cancer drug bexobrutideg and immunology and inflammation opportunities continuing to offer potential, RBC Capital Markets said in a note Thursday.Roche's expertise should enhance the market potential for bexobrutideg in chronic lymphocytic leukemia while reducing development costs, the investment firm said, as it raised its estimates for bexobrutideg's US opportunity to $1.7 billion from $1.4 billion previously.The firm also sees the company's inflammation and immunology pipeline as an underappreciated growth driver, with multiple clinical catalysts expected later this year.RBC Capital Markets raised its price target to $33 from $30, while maintaining an outperform, speculative risk rating on Nurix.Shares of Nurix were down 1.1% in premarket activity Friday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NRIX":"Nurix Therapeutics","BK4207":"综合性银行","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","BK4139":"生物科技","GSIB":"THEMES GLOBAL SYSTEMICALLY IMPORTANT BANKS ETF","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC"},"translate_title":"加拿大皇家银行资本市场表示，Nurix Therapeutics 与罗氏的交易有望推动长期上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NRIX":1.5,"GSIB":0.6},"content_text":"Nurix Therapeutics (NRIX) is well positioned for long-term growth, with its Roche partnership expanding the commercial opportunity for lead investigational cancer drug bexobrutideg and immunology and inflammation opportunities continuing to offer potential, RBC Capital Markets said in a note Thursday.Roche's expertise should enhance the market potential for bexobrutideg in chronic lymphocytic leukemia while reducing development costs, the investment firm said, as it raised its estimates for bexobrutideg's US opportunity to $1.7 billion from $1.4 billion previously.The firm also sees the company's inflammation and immunology pipeline as an underappreciated growth driver, with multiple clinical catalysts expected later this year.RBC Capital Markets raised its price target to $33 from $30, while maintaining an outperform, speculative risk rating on Nurix.Shares of Nurix were down 1.1% in premarket activity Friday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2650106180","isCrawlerRequest":true}